Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Mortality in Graves’ Orbitopathy is Increased and Influenced By Gender, Age and Pre-Existing Morbidity: A Nationwide Danish Register Study
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2017
authors: Schwensen CF, Brandt F, Hegedüs L, Brix TH
summary/abstract:Introduction:
It is unclear whether the excess mortality associated with Graves’ disease differs between individuals with Graves’ orbitopathy (GO) or without (GD).
Subjects and Methods:
A nationwide, register-based cohort study in which all adult Danes diagnosed with GD (n = 28 461) and GO (n = 3965) between 1995 and 2012 were matched for age and gender with four control subjects. Median follow-up time was 7.9 years (range 0-17.5). Mortality risk in GO patients compared to the control population and compared to GD patients was calculated using Cox regression analyses, adjusting for pre-existing morbidity using the Charlson score.
Results:
Adjusted mortality in Graves’ disease overall (GD + GO) was significantly increased compared to that in the background population (HR = 1.18 (95% confidence interval: 1.15-1.21)). In GD and GO separately, adjusted mortality was also significantly higher than that in their respective control populations (HR: 1.19 (1.16-1.22) and HR: 1.23 (1.12-1.35) respectively). However, mortality in GO compared to that in GD was decreased (HR: 0.64 (0.59-0.69)), although this difference attenuated after adjustment for pre-existing morbidity, age and gender. Both GD and GO males had a significantly higher mortality than those in females. For GO, but not for GD, mortality risk was the highest in the youngest and decreased with increasing age.
Conclusions:
GD and GO were associated with increased mortality, especially in males. In GO, but not in GD patients, there was an inverse relationship between age and mortality. Surprisingly, and in need of further study, mortality was not higher in GO than that in GD individuals.
DOI: 10.1530/EJE-16-0954
read more full text
Related Content
-
FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)The U.S. Food and Drug Administration (F...
-
Sensitivity and Responsiveness of the Patient-Reported TED-QOL to Rehabilitative Surgery in Thyroid Eye DiseaseWe tested the sensitivity and responsive...
-
Christina’s Thyroid Eye Disease Journey – Dr. Raymond Douglashttps://www.youtube.com/watch?v=XM3Yq43x...
-
Dealing With Thyroid Eye Disease: Patient and Physician PerspectivesJoin us for a webinar hosted by the Grav...
-
...Hyperthyroidism is caused when the thyro...
-
Surgical Treatment of Diplopia in Graves’ Orbitopathy PatientsPurpose: To review the authors' current...
-
Anatomic Considerations in Thyroid Eye DiseasePurpose: To review and summarize the cl...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.